Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression

Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined. However, it is necessary to take into account all the properties of propranolol to select a drug that...

Descripción completa

Detalles Bibliográficos
Autores principales: Brohée, Laura, Peulen, Olivier, Nusgens, Betty, Castronovo, Vincent, Thiry, Marc, Colige, Alain C., Deroanne, Christophe F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935740/
https://www.ncbi.nlm.nih.gov/pubmed/29728578
http://dx.doi.org/10.1038/s41598-018-25340-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935740/
https://www.ncbi.nlm.nih.gov/pubmed/29728578
http://dx.doi.org/10.1038/s41598-018-25340-9

Ejemplares similares